Octagon Research Solutions Sponsors the Pharamceutical Performance Institute
Cross-Organizational Performance Optimization to be Discussed at Groundbreaking Conference
Wayne, PA -- May 16, 2005 -- Octagon Research Solutions, the leader in the electronic transformation of clinical R&D, announced today that it has joined a small yet diverse collection of technology providers to sponsor the Pharmaceutical Performance Institute. The Pharmaceutical Performance Institute (PPI) is comprised of technology leaders that develop innovative solutions for the life sciences industry aimed at improving performance across the organization including regulatory, clinical, contract management, marketing and sales. The group was formed around the idea that technologies and processes must surmount traditional functional barriers in order to gain true efficiencies. The sponsor organizations offer innovative technology solutions that change the way the biopharmaceutical industry works by applying process automation to mission critical events.
"Octagon continues to push the envelope when it comes to performance optimization," states Jim Walker, president and CEO. "We strive to utilize innovative technologies to improve our own performance and we are also committed to sharing our practical expertise with our expanding customer base."
The Pharmaceutical Performance Institute will be hosting the Performance Optimization Conference on July 1, 2005 in New York City. Presenters at the event include pharmaceutical industry thought leaders as well as technology experts in the field of performance optimization.
Walker also notes, "Through well-defined processes, extensive expertise and innovative technologies, we have developed a novel approach to process optimization. The Pharmaceutical Performance Institute provides a perfect forum to share our expertise with leaders of the industry." Mr. Walker will be presenting at the June 1st conference on the topic of "Performance Optimization in the Regulatory Arena."
For more information on the Pharmaceutical Performance Institute, please visit the url: www.octagonresearch.com/ppievent/InvitationMain.html
About Octagon Research Solutions, Inc.
Octagon is a leading process-centric solutions provider that offers a suite of regulatory, clinical, process and IT solutions to the life sciences industry. Octagon synchronizes processes and increases automation to reduce island-to-island inefficiencies within the clinical research and development process. We leverage the power of electronic submissions through cross-functional eSub expertise, a holistic process approach, deep domain knowledge and creative use of technology. Octagon is headquartered Wayne, PA, with offices in Boston, MA and Cost Mesa, CA. For more information please visit www.octagonresearch.com.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
